.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Teva
US Department of Justice
Moodys
Cipla
QuintilesIMS
AstraZeneca
Baxter
Covington

Generated: December 17, 2017

DrugPatentWatch Database Preview

NOVOLIN N Drug Profile

« Back to Dashboard

Which patents cover Novolin N, and what generic alternatives are available?

Novolin N is a drug marketed by Novo Nordisk Inc and is included in two NDAs.

The generic ingredient in NOVOLIN N is insulin susp isophane recombinant human. There are thirty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin susp isophane recombinant human profile page.

Summary for NOVOLIN N

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: 3
Clinical Trials: 10
Drug Prices:see details
DailyMed Link:NOVOLIN N at DailyMed
Drug patent expirations by year for NOVOLIN N

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk IncNOVOLIN Ninsulin susp isophane semisynthetic purified humanINJECTABLE;INJECTION019065-001Jan 23, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Novo Nordisk IncNOVOLIN Ninsulin susp isophane recombinant humanINJECTABLE;INJECTION019959-001Jul 1, 1991OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Army
Moodys
McKinsey
Chinese Patent Office
Cantor Fitzgerald
Harvard Business School
QuintilesIMS
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot